Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 269

1.

Effect of GWAS-Identified Genetic Variants on Maximum QT Interval in Patients With Schizophrenia Receiving Antipsychotic Agents: A 24-Hour Holter ECG Study.

Watanabe J, Fukui N, Suzuki Y, Sugai T, Ono S, Tsuneyama N, Saito M, Tajiri M, Someya T.

J Clin Psychopharmacol. 2017 Aug;37(4):452-455. doi: 10.1097/JCP.0000000000000724.

PMID:
28590366
2.
3.

Brugada Syndrome.

Brugada R, Campuzano O, Sarquella-Brugada G, Brugada P, Brugada J, Hong K.

In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Ledbetter N, Mefford HC, Smith RJH, Stephens K, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2017.
2005 Mar 31 [updated 2016 Nov 17].

4.

Electrocardiographic surveillance in a psychiatric institution: avoiding iatrogenic cardiovascular death.

Rodríguez-Leal CM, López-Lunar E, Carrascosa-Bernáldez JM, Provencio-Arranz RM.

Int J Psychiatry Clin Pract. 2017 Mar;21(1):64-66. doi: 10.1080/13651501.2016.1234623. Epub 2016 Sep 30.

PMID:
27686282
5.

Haloperidol aggravates transverse aortic constriction-induced heart failure via mitochondrial dysfunction.

Shinoda Y, Tagashira H, Bhuiyan MS, Hasegawa H, Kanai H, Fukunaga K.

J Pharmacol Sci. 2016 Jul;131(3):172-83. doi: 10.1016/j.jphs.2016.05.012. Epub 2016 Jun 4.

6.

Severe proarrhythmic potential of risperidone compared to quetiapine in an experimental whole-heart model of proarrhythmia.

Frommeyer G, von der Ahe H, Brücher B, Dechering DG, Lange PS, Reinke F, Wasmer K, Köbe J, Pott C, Mönnig G, Eckardt L.

Naunyn Schmiedebergs Arch Pharmacol. 2016 Oct;389(10):1073-80. doi: 10.1007/s00210-016-1274-y. Epub 2016 Jul 12.

PMID:
27405774
7.

Low proarrhythmic potential of citalopram and escitalopram in contrast to haloperidol in an experimental whole-heart model.

Frommeyer G, Brücher B, von der Ahe H, Kaese S, Dechering DG, Kochhäuser S, Bogossian H, Milberg P, Eckardt L.

Eur J Pharmacol. 2016 Oct 5;788:192-199. doi: 10.1016/j.ejphar.2016.06.029. Epub 2016 Jun 18.

PMID:
27328775
8.

Cardiovascular safety of antipsychotics: a clinical overview.

Polcwiartek C, Kragholm K, Schjerning O, Graff C, Nielsen J.

Expert Opin Drug Saf. 2016 May;15(5):679-88. doi: 10.1517/14740338.2016.1161021. Epub 2016 Apr 1. Review.

PMID:
26934282
9.

Risk management of QTc-prolongation in patients receiving haloperidol: an epidemiological study in a University hospital in Belgium.

Vandael E, Vandenberk B, Vandenberghe J, Spriet I, Willems R, Foulon V.

Int J Clin Pharm. 2016 Apr;38(2):310-20. doi: 10.1007/s11096-015-0242-9. Epub 2016 Jan 9.

PMID:
26749342
10.

Intravenous Ondansetron and the QT Interval in Adult Emergency Department Patients: An Observational Study.

Moffett PM, Cartwright L, Grossart EA, O'Keefe D, Kang CS.

Acad Emerg Med. 2016 Jan;23(1):102-5. doi: 10.1111/acem.12836. Epub 2015 Dec 31.

11.

A Large Retrospective Cohort of Patients Receiving Intravenous Olanzapine in the Emergency Department.

Martel ML, Klein LR, Rivard RL, Cole JB.

Acad Emerg Med. 2016 Jan;23(1):29-35. doi: 10.1111/acem.12842. Epub 2015 Dec 31.

12.

[What Lessons Should We Learn from the Death of Patients on Xeplion?].

Fujii Y.

Seishin Shinkeigaku Zasshi. 2015;117(2):132-45. Review. Japanese.

PMID:
26514053
13.

The Contribution of National Spontaneous Reporting Systems to Detect Signals of Torsadogenicity: Issues Emerging from the ARITMO Project.

Raschi E, Poluzzi E, Salvo F, Koci A, Suling M, Antoniazzi S, Perina L, Hazell L, Moretti U, Sturkenboom M, Garbe E, Pariente A, De Ponti F.

Drug Saf. 2016 Jan;39(1):59-68. doi: 10.1007/s40264-015-0353-1.

14.
15.

Sudden cardiac and sudden unexpected death related to antipsychotics: A meta-analysis of observational studies.

Salvo F, Pariente A, Shakir S, Robinson P, Arnaud M, Thomas S, Raschi E, Fourrier-Réglat A, Moore N, Sturkenboom M, Hazell On Behalf Of Investigators Of The Aritmo Consortium L; Investigators of the ARITMO Consortium.

Clin Pharmacol Ther. 2016 Mar;99(3):306-14. doi: 10.1002/cpt.250. Epub 2015 Nov 20.

PMID:
26272741
16.

The cardiac safety of aripiprazole treatment in patients at high risk for torsade: a systematic review with a meta-analytic approach.

Polcwiartek C, Sneider B, Graff C, Taylor D, Meyer J, Kanters JK, Nielsen J.

Psychopharmacology (Berl). 2015 Sep;232(18):3297-308. doi: 10.1007/s00213-015-4024-9. Epub 2015 Aug 1. Review.

PMID:
26231497
17.

Risk factors for sudden cardiac death among patients with schizophrenia.

Hou PY, Hung GC, Jhong JR, Tsai SY, Chen CC, Kuo CJ.

Schizophr Res. 2015 Oct;168(1-2):395-401. doi: 10.1016/j.schres.2015.07.015. Epub 2015 Jul 22.

PMID:
26210551
18.

Drug-induced proarrhythmia: risk factors and electrophysiological mechanisms.

Frommeyer G, Eckardt L.

Nat Rev Cardiol. 2016 Jan;13(1):36-47. doi: 10.1038/nrcardio.2015.110. Epub 2015 Jul 21. Review.

PMID:
26194552
19.

Haloperidol and sudden cardiac death in dementia: autopsy findings in psychiatric inpatients.

Ifteni P, Grudnikoff E, Koppel J, Kremen N, Correll CU, Kane JM, Manu P.

Int J Geriatr Psychiatry. 2015 Dec;30(12):1224-9. doi: 10.1002/gps.4277. Epub 2015 Mar 19.

PMID:
25790441
20.

Psychotropic medications and the risk of sudden cardiac death.

Huikuri HV.

J Am Heart Assoc. 2015 Feb 23;4(2). pii: e001894. doi: 10.1161/JAHA.115.001894. No abstract available.

Supplemental Content

Loading ...
Support Center